Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandatory, Voluntary Recalls Distress Supplement Firms

This article was originally published in The Pink Sheet Daily

Executive Summary

Because a consent decree stipulated FDA could order Kabco Pharmaceuticals to recall products if the firm was found in violation, the enforcement did not emanate from the agency’s mandatory recall authority. Purity First Products, meanwhile, argues that FDA wrongly claimed the firm refused to conduct a recall.

You may also be interested in...



Mandatory Recall Guidance Positions FDA For ‘Robust’ Use Of Authority

Final guidance on mandatory recall authority under FSMA specifies how FDA allows firms opportunities for voluntary recalls and evidence it may consider when deciding whether to mandate a recall. But a consumer advocacy group critical of FDA says the guidance adds nothing for protecting public health.

Las Vegas Kratom Marketer Rolls Dice On FDA's Mandatory Recall Authority

FDA for the first time exercises its mandatory recall authority over food and supplement products to order Triangle Pharmanaturals, which opened for business in Las Vegas in April 2017, to recall all of the kratom-containing products it has distributed and to cease distributing additional products.The agency also notes in the announcement that it continues to scrutinize kratom's safety unrelated to contamination.

Medical Food Firm's Production Investigated After Rash Of Adverse Events

FDA receives 194 adverse event reports regarding Primus Pharmaceuticals''s Limbrel medical food capsules, including two about "potentially life-threatening medical conditions." The agency says a likely relation was found between the product and the conditions reported in 30 of the AERs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel